 CAMBRIDGE, Mass.--BUSINESS WIRE--bluebird bio, Inc. NASDAQ: BLUE today reported financial results and business highlights for the fourth quarter and full year ended December 31, 2019. 2019 was truly a transformative year for bluebird, with our first commercial product now launched in Europe and exciting progress across our first four clinical programs and pipeline, said Nick Leschly, chief bluebird. Notably, our data in SCD continues to build, and at the ASH annual meeting in December we 